AAN 2021 – Helios backs Alnylam’s sunny forecasts

AAN 2021 – Helios backs Alnylam’s sunny forecasts

Source: 
EP Vantage
snippet: 

Since Alnylam first toplined vutrisiran’s Helios-A study data in January the sellside has marked up forecast revenues for the amyloidosis project by a third. Full data from this phase 3 trial, which is key to the group’s franchise extension, suggest this upgrade to have been justified.